BUZZ - CG Oncology stock rises as clinical trials show its drug reduces risk of tumor recurrence
路透社2026/11/16 13:36November 16 - ** Shares of CG Oncology (CGON.O) rose 32.95% to $98.88 in premarket trading
** The company stated that its experimental immunotherapy, cretostimogene, reduced the risk of tumor recurrence by 68% compared to the control group in a certain type of bladder cancer patients
** The late-stage clinical trial enrolled a total of 367 patients
** The company added that, given the inclusion of additional data, it now expects to complete the submission of its marketing application to the U.S. Food and Drug Administration (FDA) by the end of March 2027
** As of the previous trading day's close, the stock had gained 79% year-to-date
(To assist non-native English speakers, Reuters offers automated translations of its reports into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the translated text and provides automated translation solely for reader convenience. Reuters assumes no responsibility for any damage or losses resulting from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Stock Market Movement | Chip Stocks Mostly Fall Pre-market, SanDisk (SNDK.US) Drops Over 6%
On Monday, chip stocks fell broadly in pre-market trading. SanDisk (SNDK.US) dropped over 6%, while Micron Technology (MU.US) declined by 6%.

Tesla (TSLA.US) Takes the First Step Toward Cybercab Popularization: First Invitation for Individual Customers to Purchase
Tesla has invited select customers to purchase the Cybercab, priced at $29,990, with a required monthly subscription fee of $299. The use is limited to personal purposes only, and it is prohibited to operate the vehicle on ride-hailing platforms. Deliveries may begin as early as December.

AirJoule Technologies Q3 2026 net loss more than doubles quarter-on-quarter to $19.8 million
An “important step” in the AI revolution! Anthropic (ANT.US) IPO debuting this week, Ives: A valuation firmly at $1.25 trillion will validate the cloud giants’ capital expenditure logic.
Anthropic will launch its initial public offering (IPO) this week. Yorkville Ives analyst Dan Ives believes that this listing will be an "important step" for the expansion of the AI industry and the broader technology sector.